
Medicare and Wegovy in 2026: The GLP-1 Bridge and $50 Copay
Medicare covers Wegovy via Part D for heart risk, or the GLP-1 Bridge for weight loss at $50 a month through 2027. Eligibility, Extra Help and 2027 prices.
Written by Diana Gangan. Updated November 12, 2026.
Yes, Medicare can cover Wegovy in 2026, but how it does so depends on why it is prescribed. If you take Wegovy to lower heart risk because you have heart disease plus overweight or obesity, your Medicare Part D drug plan can cover it under its normal rules, including prior approval and your plan's copay. If you take it only for weight loss, Part D still cannot pay, but a temporary program called the Medicare GLP-1 Bridge has covered Wegovy for weight management at a flat $50 a month since July 1, 2026, and it runs until December 31, 2027. Wegovy is also approved for a type of fatty liver disease called MASH; Part D plans may cover that use, but we found no CMS statement confirming it, and people with fatty liver disease are excluded from the Bridge. This guide explains both routes, who qualifies, how Medicare Advantage and Extra Help fit in, and what changes in 2027, as of November 2026.
Medicare and Wegovy in 2026: The Short Answer
- 1Two routes: Part D for heart-risk (and possibly MASH) use, and the GLP-1 Bridge for weight management only.
- 2GLP-1 Bridge: $50 a month, July 1, 2026 to December 31, 2027, with BMI-based eligibility rules.
- 3Bridge limits: the $50 does not count toward the Part D out-of-pocket cap, and Extra Help does not apply.
- 4Excluded from the Bridge: people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease.
- 5Part D route: your plan's formulary, prior authorization and copay apply; costs count toward the $2,100 cap for 2026.
- 62027: a Medicare negotiated price for semaglutide starts January 1, and Wegovy's list price drops to $675 a month.
Does Medicare Cover Wegovy in 2026?
Medicare has a long-standing rule that Part D drug plans cannot cover medicines used for weight loss alone. That rule has not changed. What changed is that Wegovy gained uses beyond weight loss. According to its FDA label, the Wegovy injection is approved to reduce the risk of major heart events in adults with established cardiovascular disease and obesity or overweight, for chronic weight management, and for noncirrhotic MASH with moderate-to-advanced liver scarring (fibrosis stages F2 to F3). The Wegovy tablets are approved for the heart and weight uses, but not for MASH.
So in 2026 there are two separate doors. The Part D door is for a medically accepted use other than weight loss. The Bridge door is for weight management and runs outside Part D entirely. Which one applies depends on your diagnosis, not on which plan you have. For private and employer insurance, see does insurance cover Wegovy.
Does Medicare Part D Cover Wegovy for Heart Disease?
It can. After the FDA approved Wegovy's heart indication on March 8, 2024, a CMS spokesperson told Reuters that a weight-loss drug with an additional medically accepted use, such as reducing heart risk in adults with heart disease and obesity or overweight, can be covered by Part D for that use only. Each plan still decides how: it may require prior authorization, place Wegovy on a particular tier, or not list it, and your share of the cost follows your plan's rules. What you pay counts toward the 2026 Part D out-of-pocket cap of $2,100. The 2026 standard deductible is $615.
Uptake was slow at first. A 2026 study found Part D fills of Wegovy rose from 4,689 in February 2024 to 32,732 in September 2024, under 1% of an estimated 3.6 million eligible beneficiaries. The heart trial behind this indication is covered in the Wegovy SELECT trial.
Does Medicare Cover Wegovy for MASH or Fatty Liver Disease?
Possibly, through Part D, but this is less certain. The FDA granted Wegovy accelerated approval for MASH (metabolic dysfunction-associated steatohepatitis) in August 2025, for the injection only. In the label's trial, 63% of people on Wegovy had resolution of liver inflammation at 72 weeks versus 34% on placebo, and 37% versus 22% had less fibrosis. Medicare.gov says plans may cover GLP-1 drugs for fatty liver disease, but we found no CMS statement that explicitly confirms Part D coverage of Wegovy for MASH. Ask your plan directly before you start. One thing is clear: fatty liver disease is on the Bridge's exclusion list, so people with MASH cannot use the $50 program. More on this use in Wegovy for fatty liver and MASH.
What Is the Medicare GLP-1 Bridge and the $50 Copay?
The Medicare GLP-1 Bridge is a temporary CMS program that covers certain GLP-1 drugs for weight management. According to CMS, it runs from July 1, 2026 to December 31, 2027 and operates outside the Part D benefit. It was extended through 2027 because a planned replacement, the BALANCE Model, will not launch in 2027. Covered drugs are Wegovy (injection or tablet), Zepbound KwikPen and Foundayo. Key rules:
- 1You pay a $50 copay per month's supply, and the Part D deductible does not apply.
- 2The $50 does not count toward your Part D out-of-pocket cap.
- 3Extra Help (the Low-Income Subsidy) does not lower the $50.
- 4The copay cannot be spread out using the Medicare Prescription Payment Plan and does not appear on your Part D Explanation of Benefits.
- 5A central processor handles prior authorization and claims; KFF Health News reported that Humana is CMS's prior authorization contractor.
Wegovy injection and tablet options are compared in Wegovy pill vs injection.
Who Qualifies for the GLP-1 Bridge?
According to the Medicare.gov fact sheet, you must be 18 or older and meet one of these BMI-based criteria:
- 1BMI of 35 or more
- 2BMI of 30 or more plus heart failure (diastolic), uncontrolled high blood pressure or chronic kidney disease stage 3a or worse
- 3BMI of 27 or more plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
You are excluded if you already get a GLP-1 through Part D, or if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea or fatty liver disease. People in some plan types, including private fee-for-service, cost plans and PACE-only coverage, are also excluded. People taking a GLP-1 for heart risk, sleep apnea or diabetes stay in their regular Part D plan and may pay more than $50. KFF estimated that about 3.8 million beneficiaries met the eligibility criteria, based on 2023 data.
Two Medicare routes to Wegovy in 2026
Who qualifies
Medically accepted use: established heart disease plus obesity or overweight; MASH coverage not confirmed by CMS
Age 18+ meeting BMI criteria; excludes type 2 diabetes, moderate-to-severe sleep apnea, fatty liver disease
What you pay
Your plan's cost sharing (varies)
$50 a month, no deductible
Counts toward out-of-pocket cap
Yes ($2,100 in 2026)
No
Extra Help
Applies under normal Part D rules
Does not apply
Prior authorization
Set by your plan
Through a central processor
Medicare Advantage drug plans
Yes, plan rules apply
Yes, MA-PD enrollees can qualify
Dates
Ongoing (heart use since March 2024)
July 1, 2026 to December 31, 2027
Does Medicare Advantage Cover Wegovy Differently?
The same two routes apply. If your Medicare Advantage plan includes drug coverage (an MA-PD), it follows the Part D rules for heart-risk use, with its own formulary and prior authorization. For the Bridge, Medicare.gov and Pharmacy Times list enrollees in standalone drug plans, MA-PD plans, Special Needs Plans, employer group plans and the LI NET program as eligible. Private fee-for-service, cost plan and PACE-only enrollees are not. Call the number on your plan card to check your plan's formulary.
Does Extra Help Lower the Wegovy Copay?
Not for the Bridge: CMS states the Low-Income Subsidy does not apply to the $50 copay. For Wegovy covered under Part D for heart risk, Extra Help works the way it does for other covered drugs and can lower your cost sharing. We did not find data on what people actually pay for Wegovy in Part D in 2026, since that depends on the plan and tier.
What Will Wegovy Cost on Medicare in 2027?
Several changes are scheduled for January 1, 2027. Semaglutide's Medicare negotiated price (called the maximum fair price) takes effect: CMS data summarized by AMCP give a headline price of $274, and $385.63 for a four-pen pack of Wegovy 2.4 mg. That is the price Medicare plans pay, not your copay; AARP reported that enrollee cost sharing will likely be lower. Separately, Novo Nordisk announced that Wegovy's list price will fall to $675 a month from January 1, 2027. For comparison, a 2025 trade report cited a list price of $1,349; we did not verify the 2026 list price.
The Part D out-of-pocket cap for 2027 is reported as $2,400 by Humana, an insurer, but we did not find that figure in a CMS document; CMS's 2027 rule summary gives no dollar amount. Treat $2,400 as unconfirmed until your plan's 2027 documents show it. Novo Nordisk also committed to a $245 Medicare price for semaglutide starting in 2026, but how that interacts with Part D claims and the negotiated price is unclear. Ways to lower costs outside Medicare are in Wegovy cost and savings.
Medicare and Wegovy: 2026 vs 2027
Part D out-of-pocket cap
$2,100
$2,400 (reported by Humana only; not confirmed by CMS)
Part D standard deductible
$615
Not verified
GLP-1 Bridge copay
$50 a month (from July 1)
$50 a month (through December 31)
Wegovy Medicare negotiated price
Not in effect
$385.63 per 4 pens of 2.4 mg ($274 semaglutide headline)
Wegovy list price
$1,349 cited in August 2025; current 2026 figure not verified
$675 a month (Novo Nordisk)
What Happens When the Bridge Ends in December 2027?
Nothing has been confirmed. CMS extended the Bridge through 2027 because the BALANCE Model will not launch that year, and we found no announcement of what will replace it after December 31, 2027. If you might have to stop the drug when coverage changes, see what happens when you stop taking Wegovy. Check for updates during the 2027 enrollment period.
When to Talk to Your Doctor
- 1You have heart disease and excess weight: ask whether Wegovy should be prescribed for heart-risk reduction, which goes through Part D
- 2You have type 2 diabetes, sleep apnea or fatty liver disease, which exclude you from the Bridge
- 3You cannot tolerate side effects or are considering a different dose, such as Wegovy HD 7.2 mg
- 4You plan to stop Wegovy because of cost changes
- 5You are switching between the injection and the tablet
How Do I Get Wegovy Covered by Medicare? Next Steps
- 1Ask your prescriber which use the prescription is for: heart risk, MASH or weight management.
- 2For heart risk or MASH, check your Part D or MA-PD formulary and ask about prior authorization and tier.
- 3For weight management, check the BMI criteria and exclusions on Medicare.gov's GLP-1 Bridge page.
- 4Ask your prescriber to submit the prior authorization through the correct route.
- 5Ask your pharmacy whether the claim is processing under Part D or the Bridge.
- 6Review 2027 plan documents for your cap and Wegovy cost sharing.
Once approved, dose steps are explained in the Wegovy dosing schedule.
The Bottom Line
In 2026, Medicare covers Wegovy in two ways: through Part D for heart-risk reduction (and possibly MASH), with plan cost sharing that counts toward the $2,100 cap, or through the GLP-1 Bridge for weight management at $50 a month until December 31, 2027. The Bridge excludes people with diabetes, moderate-to-severe sleep apnea or fatty liver disease, and Extra Help does not apply. Prices fall in 2027, but the new cap and what replaces the Bridge are not yet confirmed by CMS.
FAQ
Not through Part D, but the Medicare GLP-1 Bridge covers it for weight management at $50 a month from July 1, 2026 to December 31, 2027, if you meet the criteria.
Age 18+ and a BMI of 35+, 30+ with certain conditions, or 27+ with others. Type 2 diabetes, moderate-to-severe sleep apnea and fatty liver disease exclude you.
Yes, Part D plans can cover it for adults with established heart disease and obesity or overweight, under the plan's own rules and cost sharing.
Plans may cover the injection for MASH through Part D, but CMS has not explicitly confirmed it. People with fatty liver disease are excluded from the Bridge.
MA plans with drug coverage follow Part D rules for heart-risk use, and their members can qualify for the Bridge. PFFS and PACE-only enrollees cannot.
Medicare's negotiated price is $385.63 per four 2.4 mg pens from January 1, 2027. Your copay depends on your plan.
Sources
- 1Novo Nordisk. Wegovy (semaglutide) injection and tablets prescribing information, revised 05/2026, U.S. Food and Drug Administration, 2026
- 2CMS. Medicare GLP-1 Bridge, Centers for Medicare & Medicaid Services, 2026
- 3Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month: what you need to know for July 1, 2026 (Product No. 12234), Medicare.gov, 2026
- 4Weight loss drugs coverage, Medicare.gov, 2026
- 5CMS. Final CY 2026 Part D redesign program instructions, Centers for Medicare & Medicaid Services, 2025
- 6CMS. Contract Year 2027 Medicare Advantage and Part D final rule, Centers for Medicare & Medicaid Services, 2026
- 7FDA. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, FDA news release via BioSpace, 2024
- 8FDA grants accelerated approval of Wegovy to treat liver disease, Managed Healthcare Executive, 2025
- 9Medicare to cover Wegovy for certain indications, Pharmaceutical Executive, 2024
- 10Scannell C et al. Changes in semaglutide fills following expanded FDA and Medicare policies, American Journal of Managed Care, 2026
- 11Nearly four million Medicare beneficiaries could be eligible for the temporary Medicare GLP-1 Bridge program covering these drugs for weight loss, KFF, 2026
- 12Fortiér J. A new Medicare option for weight loss drugs: what older Americans should know, KFF Health News, 2026
- 13Halpern L. Medicare's new GLP-1 Bridge program: what pharmacists need to know before dispensing, Pharmacy Times, 2026
- 14AMCP. Federal update: CMS releases negotiated prices for 15 drugs under Medicare Drug Price Negotiation Program, Academy of Managed Care Pharmacy, 2025
- 15Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus, Novo Nordisk press release via BioSpace, 2026
This article summarizes government, FDA and published sources for general information and is not medical, insurance or legal advice. Medicare rules and prices can change; confirm details with your plan or Medicare. The Wegovy trials cited were funded by Novo Nordisk.

Diana Gangan
Author
Comments (0)
Be the first to comment on this article.




